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Mesalazine (5-ASA) is the standard drug for the treatment of inflammatory bowel disease (IBD) due to 
its local effect on intestinal and colonic mucosa. The effective and safe treatment of this disease requires 
more efficient delivery of the active substance to its site of action. The focus of this study was the use 
of multiparticulate systems, a modified release form in which the drug is divided into several functional 
subunits of release in the form of granules or pellets. When these forms are administered, they are rapidly 
disintegrated, distributing their content throughout the gastrointestinal tract. The aim of this study was to 
develop and evaluate a multiparticulate system consisting of pellets coated with polymer for pH-dependent 
release, derived from methacrylic acid and incorporated into the tablet dosage form of mesalazine as a 
model drug. The extrusion-spheronisation technique was used, resulting in smooth and spherical pellets 
with uniform size distribution, which were coated in fluidized bed using Opadry® Enteric 94K28327 
containing Eudragit® S100 as the agent regulating drug release. The dissolution profile of coated pellets 
showed good control of drug release from the polymer at the two levels of coating evaluated (8% and 
10%), but only the 10% coated pellets were statistically similar to Asalit® 400 mg.
Uniterms: Mesalazine. Coated pellets/evaluation. Coated pellets/dissolution profile. Extrusion-
Spheronisation/pellets obtention. Drugs/modified release.
A mesalazina (5-ASA) tem se apresentado como fármaco padrão para o tratamento da doença inflamatória 
intestinal (DII) devido ao seu efeito local na mucosa intestinal e colônica. A terapia efetiva e segura desta 
doença requer a chegada da substância ativa ao seu local de ação com maior eficiência. Nessa busca, 
tem se destacado o uso de Sistemas Multiparticulados, forma farmacêutica de liberação modificada, em 
que o fármaco está dividido em várias subunidades funcionais de liberação, sob a forma de grânulos ou 
péletes, que quando administrados, são rapidamente desintegrados distribuindo seu conteúdo por todo trato 
gastrintestinal. Este trabalho teve como objetivo desenvolver e avaliar péletes revestidos com polímero 
de liberação pH-dependente, derivado do ácido metacrílico, tendo como fármaco modelo a mesalazina. 
A técnica de extrusão-esferonização foi utilizada obtendo-se péletes lisos e esféricos com distribuição 
granulométrica uniforme, que foram revestidos em leito fluidizado utilizando Opadry® Enteric 94K28327 
contendo Eudragit® S100 como agente regulador da liberação do fármaco. O perfil de dissolução dos 
péletes revestidos demonstrou bom controle na liberação do fármaco por parte do polímero nos dois 
níveis de revestimento avaliados (8 e 10%), porém, apenas os péletes revestidos a 10% demonstraram 
semelhança estatística com o medicamento de referência Asalit® 400 mg.
Unitermos: Mesalazina. Péletes revestidos/avaliação. Péletes revestidos/perfil de dissolução. Extrusão-
esferonização/obtenção de péletes. Fármacos/liberação modificada.
INTRODUCTION
Inflammatory bowel disease (IBD) denotes a group 
of diseases that primarily affect the small and large in-
testines, and is characterized as chronic inflammation of 
unknown etiology. IBD is subdivided into ulcerative colitis 
(limited to the colon) and Crohn’s disease (can affect any 
part of gastrointestinal tract from the esophagus to the 
anus but more often involves the small intestine and colon) 
(Cotran, Kumar, Robbins, 2000; Chuong, Christensen, 
Ayres, 2008). 
Mesalazine (5-ASA) is used as the standard drug 
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for the treatment of inflammatory bowel disease due to 
its local effect on intestinal and colonic mucosa and to its 
few side effects (Cai et al., 2003; Qureshi, Cohen, 2005). 
Despite being the focus of many studies, mesalazine’s 
mechanism of action is only partially understood, although 
it is accepted that its effect occurs locally in the intestinal 
mucosa by inhibiting cyclo-oxygenase and lipo-oxyge-
nase, thus decreasing the production of prostaglandins 
and leukotrienes. The drug is also believed to act as a 
scavenger of free radicals, produced in greater numbers in 
patients with inflammatory bowel disease (USP-DI, 2007).
Pharmaceutical Technology has played a fundamen-
tal role in the investigation of systems that efficiently deli-
ver the drug to its site of action. The focus of this study was 
the use of multiparticulate systems, modified-release form 
in which the drug is divided into many release subunits 
in the form of granules or pellets that can be incorporated 
into hard gelatin capsule or compressed forms (Collet, 
Moreton, 2005).
Pellets are spheres measuring between 500 and 
1500 μm in diameter with applications in both the phar-
maceutical and fertilizer industries. Pellets have several 
technological and therapeutical advantages such as opti-
mum flow properties, narrow particle size distribution, 
surface-susceptible coating film offering enteric protection 
or controlled release, and wide dispersion in the gas-
trointestinal tract. This serves to reduce tract irritation by 
gastro-irritant drugs and lower the risk of adverse effects 
due to overdose (Santos et al., 2004).
Among the techniques employed for preparing pel-
lets, extrusion-spheronization has gained special attention 
because of its easy of application and resultant pellets 
with highly uniform particle size distribution which can 
be coated or compressed, yielding cores for subsequent 
polymer coatings able to control the drug dissolution 
process (Villar-Lopez et al., 1999; Krogars et al., 2000; 
Gupta et al., 2001).
The use of a multiparticulate system for drug deli-
very in preference to a monolithic system was proposed 
by Hardy et al. (1985), after demonstrating that the units 
of the multiparticulate system were able to reach the colon 
quickly and be retain there for a long period of time. Due 
to the smaller particle size of multiparticulate forms com-
pared to monolithic forms, multiparticulate systems are 
able to disperse more easily through the gastrointestinal 
tract, promoting more uniform and safe drug absorption.
The aim of this study was to develop a multiparti-
culate system containing mesalazine pellets coated with 
pH-dependent methacrylic derived polymer, with further 
characterization and evaluation of the drug release profile 
in vitro compared with the reference product. This was 
achieved by using a dissolution medium that simulates 
changes in pH of the gastrointestinal tract, in a bid to ob-
tain a feasible strategy for the development of therapeutic 
systems that release the drug at the colon.
MATERIALS AND METHODS
Production of pellets
Mesalazine anhydrous (40%w/v) (Deg, batch 
IF080303) and Microcrystalline Cellulose 101 (60%w/v) 
(Microcel® 101, Blanver; batch 208/06) were mixed and 
added to an aqueous solution of PVP-K30 (10%w/v) (Lu-
viskol® K 30, BASF) to form a mass with plastic characte-
ristics, which was then passed through an extruder (local 
development) mesh of 1 mm in diameter. The extrudate 
was spheronised (spheroniser Caleva M120) using a disk 
12 cm in diameter (cross-hatch type) at 1000 rpm/10 min. 
The pellets were dried in a conventional hot-air oven 
Fabbe 201 (Sao Paulo, Brazil) at 40 °C for 24 hours.
Sample preparation
The pellets were classified by a set of sieves 
(0.5 mm, 0.710 mm, 1.00 mm and 1.4 mm). The size frac-
tion 0.7 mm - 1.0 mm was separated into two batches of 
samples, denominated uncoated pellets (UC) and pellets 
for coating (C).
Coating of drug pellets
The sample (C) was coated in fluidized bed 
(LM-FBD Labmac 5.0 - inlet temperature of air and pellets 
of 40 °C) and the spray rate was 2.5 mL/min. The coating 
solution (8%w/v) was prepared using a mechanical shaker 
(Fisaton 713) at 90 rpm for 30 minutes. The coating was 
applied with two levels of weight gain (8% and 10%) at 
the end of the coating process.
Pellet friability
The friability was evaluated in a friabilometer 
(Erweka GmbH, Bizen, Germany) as described by Thoma, 
Ziegler, 1998.
Shape analysis of pellets (eR)
The determination of particle shape (perimeter, 
maximum, minimum and mean diameters were used in 
determining the sphericity or shape factor eR as described 
by Podczeck et al., 1999) and the ratio radius of the sam-
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ples from the same batches was carried out by a black and 
white CCD video camera (Biocam-VI-6633-China) atta-
ched to a stereomicroscope Tecnival SQZ-SD4 (China). 
The scanned images were processed by Image Pro-Plus® 
software (version 1.2 Media Cybernetics, Silver Spring, 
MD, USA). 
Drug content in pellets
The content of mesalazine for UC, C8 and C10 was 
determined (sample of 100 mg) by ultraviolet spectrosco-
py (UV-1601 UV-Visible Spectrophotometer Shimadzu) 
at 302 nm. 
Coating Level 
The coating level of each batch (C8 and C10) was 
calculated by subtracting the content of respective mesala-
zine in coated pellets, from that found for uncoated pellets 
(Amighi, Moes, 1996).
Production of multiparticulate systems
Two multiparticulate systems were prepared (M8 
and M10) in the form of tablets, on pellets from the C8 
and C10, respectively, associated with microcrystalline 
cellulose 101 (ratio of 1:1) as buffer and protective agent 
of the coating. For each system, the individual components 
were weighed and the mixture compressed in a hydraulic 
press (Shimadzu SSP10A) (20 kg/cm2 for 10 seconds).
Dissolution profile
Samples - UC, C8, C10, M8, M10, Asalit® 400 mg 
and Pentasa® 500 mg - were evaluated on a Hanson® 
SR6 dissolutor (apparatus 2, 100 rpm, 37 °C ± 0.5 ºC) 
for twelve hours divided into three stages according to 
the methodology described by Chuong, Christensen and 
Ayres, 2008. Samples of 10 mL were withdrawn (with 
replacement) at the times 5, 15, 30, 60, 90, 120, 125, 135, 
150, 180, 210, 240, 270, 300, 360, 480 and 720 minutes. 
The concentration of dissolved drug was measured by 
spectrophotometer (Shimadzu) UV/VIS - at wavelengths 
of 302, 330 and 332 nm for the first, second and third 
stages, respectively.
RESULTS AND DISCUSSION
The average particle size obtained for pellets develo-
ped was 0.9977 mm, which is consistent with the extruder 
diameter (1 mm).
The evaluation of friability (0.95%) showed that the 
pellets have a high mechanical strength. This is due to the 
extrusion process that promoted mass compaction, pro-
ducing dense and less friable extruded mass, which after 
spheronization was made into pellets with low friability, 
able to withstand the polymer coating process to modify 
the release of mesalazine (O’Connor, Schwartz, 1989).
The parameter sphericity shape factor eR was establi-
shed by Podczek and Newton (1994, 1995), where the va-
lue of unity is considered a perfect sphere, although values 
greater than 0.6 characterize a particle of good sphericity. 
The value of еR determined for the pellets was 0.49 for 
UC, 0.50 for C8 and 0.53 for C10. There was a gradual 
increase in the value of еR accompanied by a reduction of 
the ratio between the radii, evidencing an improvement in 
the sphericity of the pellets after coating.
Table I contains the results (n = 3) determined for 
mesalazine content in a sample of 100 mg of UC, C8 and 
C10. The content of UC is in agreement with this formu-
lation and serves as a reference for determining the level 
of coating of C8 and C10. As expected, a reduction in the 
content of mesalazine in the coated lots was observed, 
proportionate to the level of coating applied.
The values for the coating level (mg%) found for 
the two developed products were in accordance with the 
planned weight gain (8% and 10% application of film 
coating) calculated based on the mesalazine content in the 
pellets without coating.
The dissolution profile of the reference product 
Asalit® 400 mg was shown to be pH dependent, consistent 
with colonic-release drugs. The release of mesalazine from 
the Asalit® tablets is regulated by a reservoir system. Af-
ter the dissolution of the coating, the release is very fast. 
The typical sigmoid shape of the curve indicates that the 
disintegration and dissolution are of comparable levels. 
The behavior at different pH values corresponds with the 
expectations: fast release at pH 7.2 and no release at pH 
6.0 and pH 1.0 (Stolk et al, 1990) (Figure 1). 
For Pentasa® tablets, the release occurs by the 
principle of dissolution by diffusion from microgranules 
TABLE I - Content of mesalazine in UC, C8, C10 And Coating 
Level of C8 And C10
Content of 
mesalazine (mg%)
Coating level 
(mg%)
Coating level 
(mg%)
UC 35.713± 0.04 -
C8 33.467± 0.06 2.246 6.30
C10 32.380± 0.21 3.333 9.48
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coated with ethylcellulose (Stolk et al., 1990). Pentasa® 
tablets in contact with the dissolution medium disintegrate 
into ethylcellulose-coated granules. The erosion in the 
ethylcellulose coating is not dependent on pH, therefore 
the highest levels of drug release in the stomach are best 
explained by the release controlled by diffusion. The 
5-ASA in the external parts of the granules dissolves rapi-
dly in acidic medium. Subsequently, the levels of release 
decrease gradually due to the time needed for the internal 
5-ASA to diffuse to the surface (Schellekens et al., 2007). 
Similar data were obtained on a different system in vitro, 
by Stolk et al. (1990).
The uncoated pellets were dissolved in simulated 
gastric fluid, attaining over 90% release in 120 minutes 
of testing, behaving as an immediate release dosage form. 
This behavior was expected, because there is no excipient 
in the composition with features that modify drug release.
The coated pellets (8 to 10%) and Asalit® 400 mg 
showed pH dependent dissolution profiles. For Asalit®, 
dissolution of the drug began only after 240 minutes of 
testing, when a change in pH to 7.2 occurred, with rele-
ase reaching over 90% after 720 minutes of testing. This 
behavior was expected given this constitutes a monolithic 
tablet coated with a gastro-resistant methacrylic-derived 
polymer (Eudragit® S) which dissolves only at pH> 7.0 
(Chuong, Christensen, Ayres, 2008).
For coated pellets (8% to 10%), a slight dissolution 
was seen at pHs below 7.2 (less than 1%), whereas signi-
ficant dissolution began only after 240 minutes of testing. 
This shows that the polymer used in the coating provided 
good control over drug release for both coating levels 
evaluated (8% and 10%), with little noticeable difference 
between them. The 10% coated pellets 10% however, de-
monstrated slightly higher retention of the drug, as a result 
of the higher amount of polymer used, and consequently 
their dissolution profile more closely resembled that of 
Asalit® (Figure 2).
In contrast to dissolution of coated pellets (8% and 
10%), where there is controlled release promoted by the 
coating, and significant drug release only at pH 7.2, in 
multiparticulate tablets from coated pellets (8% and 10%) 
the compressive force applied was found to have damaged 
the coating, facilitating the disintegration of the pellets 
and the release of the drug into the dissolution medium.
As a result of this effect, the release of the drug in 
these damaged pellets began rapidly in acidic medium, 
presenting behavior of immediate release, in which drug 
release occurs in the first few minutes of testing. It is also 
assumed that some pellets remained intact inside the tablet, 
and after being released from the dosage form behaved 
similarly to the coated pellets. Drug release was thus per-
petuated until the end of the test, generating a release pro-
file which resembled an extended release form (Figure 3).
In Figure 3, the low dissolution of the drug found 
at the pH level of 6.0 (between 120-240 minutes) can be 
explained by its proximity to the isoelectric point (pH 4.3), 
at which its solubility is lower than for other values of pH 
used (Langenbucher, 1976).
The efficiency of dissolution (ED) was calculated 
from the dissolved percentage curves versus time, after 
determining the area under the curve (AUC) and the total 
area of the graph. The results of the efficiency of disso-
lution in percent (ED%) for Asalit®, Pentasa® and the 
formulations are shown in Table II.
The ED% assessment entailed statistical analysis 
(software MSTAT-C, v.2.11) to infer the similarity between 
FIGURE 1 - Dissolution profile of reference products Asalit® and Pentasa®.
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the dissolution profiles studied. Statistical comparison 
was performed between means, using analysis of va-
riance (ANOVA-single factor), the descriptive level (P= 
4.125.10-5) and F value calculated at a significance level 
of 5% (F = 17.249; Fcritical= 3.106). The homogeneity 
of variances evaluated by Bartlett’s test (p <0.01) showed 
c2 = 1.765 compared with tabulated values of c2 α (5) = 
15.09, confirming a significant difference between the 
formulations studied. Therefore, the means of treatments 
were compared using Tukey’s test at 1% probability (D = 
0.08437) indicating that the difference between the ave-
rages were statistically significant.
No statistical difference among mean ED% of 
Pentasa® 500 mg and Asalit® 400 mg, C8 and C10 was 
FIGURE 2 - Dissolution profile of pellets (UC, C8, and C10) compared to reference drug Asalit®.
FIGURE 3 - Dissolution profile of multiparticulate systems developed.
TABLE II - Efficiency of dissolution values (%)
Product ED (%)
Asalit® 45.75 ± 1.74
Pentasa® 50.94 ± 3.42
C8 51.52 ± 1.27
C10 49.22 ± 2.4
M8 60.38 ± 2.57
M10 59.07± 2.4
S.C. Déo, I.F. Andreazza, J.C. Possamai108
found, although Asalit® and coated pellets (8% and 10%) 
both had a pH-dependent dissolution profile. This simi-
larity is probably due to the rapid drug release in these 
products upon reaching their start time of 270 min (pH 
7.2), compensating for the initial release of the drug in 
acidic medium seen in Pentasa® extending until the end 
point of the test.
The C10 sample was found to be similar to Asalit® 
400 mg, a finding which may be explained by the higher 
amount of polymer used in this coating, providing better 
control of drug release.
The multiparticulate tablets showed no similarity 
with any of the pharmaceutical forms studied, although 
they exhibited a dissolution profile that resembles exten-
ded release forms. This unexpected behavior can be ex-
plained by the presence of damaged coated pellets together 
with intact coated pellets in the dissolution medium.
CONCLUSION
The technique of pelletization by extrusion and 
spheronization resulted in the obtention of sufficiently 
spherical and smooth pellets, with a uniform size distri-
bution and adequate mechanical strength to withstand the 
coating process.
The coating process contributed toward improving 
the sphericity of the pellets.
The dissolution profile of coated pellets showed 
good control over drug release from the polymer for both 
coating levels evaluated (8% and 10%), indicating that 
the methacrylic derivative used is suitable for achieving 
modified release systems.
Only coated pellets (10%) had a similar dissolution 
profile to that of Asalit® 400 mg, according to ANOVA - 
single factor analysis.
The multiparticulate tablets showed no similarity 
to any of the pharmaceuticals forms studied, possibly due 
to rupture of the coating during the compression process.
Mesalazine pellets coated with methacrylic-derived 
polymer (10%), represents a feasible strategy to achieve 
therapeutic systems for drug release at the colon, allowing 
the possibility of producing these systems from hard ge-
latin capsules.
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